Magnesium Hydride Boosts Cholesterol Drug Effectiveness in Mice

Authors
Journal
Medical Gas Research
Year
DOI
10.4103/mgr.MEDGASRES-D-23-00047
Study Type
Mouse
Outcome
Positive
Peer Reviewed
Yes
Country
China
Health Condition
High Cholesterol
Body System
Cardiovascular

TL;DR

Scientists found that magnesium hydride (MgH2) can enhance the effects of cholesterol-lowering drugs (statins) and help reduce blood lipid levels, potentially offering a new way to treat heart disease.

Key Finding

Magnesium hydride combined with atorvastatin produced greater reductions in lipid levels in mice, potentially by slowing the breakdown of the statin drug in the liver.

Summary

Researchers tested whether magnesium hydride, a compound that releases hydrogen gas slowly in the body, could enhance the cholesterol-lowering effects of the drug atorvastatin. Using mouse studies and laboratory tests, they found that magnesium hydride reduced cholesterol levels more effectively when combined with atorvastatin, possibly by increasing how much of the drug stays active in the bloodstream.

Practical Takeaway

This is early-stage research in mice only, so it cannot yet be applied to human health. While the results suggest magnesium hydride may have promise as a complement to statin therapy, human clinical trials would be needed before any conclusions about safety or effectiveness in people could be drawn.

Abstract

There is strong evidence connecting increased serum lipid levels to cardiovascular disorders, including atherosclerosis. Statins is prescribed as the primary medication to decrease lipid levels. Recent research has demonstrated that hydrogen possesses anti-inflammatory and antioxidant properties by modulating the expression of peroxisome proliferator-activated receptor gamma coactivator-1α, ultimately leading to the preservation of lipid homeostasis. Magnesium hydride (MgH2) is a prolonged stable hydrogen storage medium, which can be utilized to investigate its synergistic lipid-lowering effect with statins and its detailed molecular mechanism, both in vivo and in vitro. To ascertain the safety and efficacy of MgH2, we executed a comprehensive research of its influence on both physiological and pathological metrics. We noted a substantial diminution in lipid levels when MgH2 was integrated with atorvastatin, as attested by oil red staining. Furthermore, we scrutinized the regulatory effect of MgH2 on cytochrome P450 3A, which is a metabolic enzyme of statins, and discovered that it could be reduced by the MgH2. Concluding from our results, we propose that MgH2 inhibits the expression of cytochrome P450 3A in the liver and exerts an auxiliary lipid-lowering effect by increasing the blood concentration of statins. By augmenting our comprehension of MgH2's role in ameliorating lipid metabolism, we aspire to develop more promising therapies in the future.